# A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients

> **NCT04152148** · PHASE1 · COMPLETED · sponsor: **Bio-Thera Solutions** · enrollment: 16 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** 500mg BAT4306F
- **BIOLOGICAL:** 750mg BAT4306F
- **BIOLOGICAL:** 900mg BAT4306F
- **BIOLOGICAL:** 1000mg BAT4306F

## Key facts

- **NCT ID:** NCT04152148
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-04
- **Primary completion:** 2021-01-13
- **Final completion:** 2021-01-13
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152148, "A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04152148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*